kras g12d targeted therapy

Kras G12D Targeted Therapy: A New Frontier in Precision Oncology

kras g12d targeted therapy has emerged as a promising approach in the realm of precision medicine, particularly for patients battling cancers driven by this specific mutation. As research advances, understanding the nuances of KRAS mutations and their implications has become pivotal in developing effective treatments. The KRAS gene, known for its role in cell signaling and growth, harbors various mutations, with G12D being one of the most common and challenging variants to target. This article delves into the complexities of KRAS G12D, the innovations in targeted therapies, and what this means for patients and clinicians alike.

Understanding KRAS G12D Mutation

KRAS, short for Kirsten rat sarcoma viral oncogene homolog, plays a critical role in regulating cell division and survival through the RAS/MAPK signaling pathway. Mutations in KRAS can cause continuous activation of this pathway, leading to uncontrolled cell proliferation—a hallmark of cancer.

Among the many KRAS mutations, G12D refers to a specific alteration where glycine (G) at position 12 is replaced by aspartic acid (D). This seemingly small change has profound effects, locking KRAS in an active state and driving oncogenesis. KRAS G12D mutations are commonly found in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, and non-small cell lung cancer (NSCLC), making it a critical target for drug development.

Why KRAS G12D Is Difficult to Target

For many years, KRAS was dubbed "undruggable" due to its high affinity for GTP/GDP and the smooth surface of the protein, which lacks obvious binding pockets for small molecules. The G12D mutation does not create new binding sites, unlike some other KRAS mutations such as G12C, which has cysteine residues that are easier to target with covalent inhibitors.

This biochemical challenge has slowed the development of effective KRAS G12D targeted therapies. As a result, patients with tumors harboring this mutation had limited options beyond conventional chemotherapy and radiation, which often come with significant side effects and limited efficacy.

Breakthroughs in KRAS G12D Targeted Therapy

Despite the hurdles, recent scientific breakthroughs have paved the way for novel therapies aimed specifically at KRAS G12D. Researchers have employed various

innovative strategies, including small molecule inhibitors, immunotherapy, and RNA-based approaches.

Small Molecule Inhibitors

The success stories around KRAS G12C inhibitors, like sotorasib and adagrasib, have inspired efforts to develop analogous drugs for G12D. Although G12D lacks the reactive cysteine residue, drug developers are exploring molecules that can bind allosterically or stabilize the inactive form of KRAS G12D.

One promising avenue involves designing compounds that exploit transient pockets formed during the switch between active and inactive states of KRAS. These molecules aim to lock KRAS G12D in its inactive GDP-bound form, thereby halting the downstream signaling cascade.

RNA Interference and mRNA Therapies

Another exciting strategy leverages RNA-based technologies such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) to specifically silence KRAS G12D expression. By degrading the mutant KRAS mRNA, these therapies can reduce the production of the aberrant protein.

Moreover, advancements in lipid nanoparticle delivery systems have enhanced the stability and tumor-targeting capabilities of these RNA molecules, increasing their therapeutic potential while minimizing off-target effects.

Immunotherapy Approaches

Immunotherapy, particularly immune checkpoint inhibitors, has revolutionized cancer treatment but has shown limited success in KRAS-mutant tumors due to their immunosuppressive microenvironment. However, combining immunotherapy with KRAS G12D targeted agents is an area of active investigation.

Additionally, cancer vaccines targeting neoantigens derived from KRAS G12D mutations are under development. These vaccines aim to prime the immune system to recognize and attack cancer cells expressing the mutant KRAS protein.

The Role of Biomarkers and Genetic Testing

Effective KRAS G12D targeted therapy hinges on precise identification of patients harboring this mutation. Comprehensive genomic profiling using next-generation sequencing (NGS) has become a standard practice in oncology clinics to detect KRAS and other actionable mutations.

Understanding the tumor’s genetic landscape not only guides the selection of targeted therapies but also informs prognosis and helps monitor treatment response. Liquid biopsies, which analyze circulating tumor DNA (ctDNA), provide a minimally invasive means to detect KRAS G12D mutations and track tumor dynamics over time.

Personalizing Treatment Plans

Integrating KRAS G12D status into clinical decision-making enables oncologists to tailor treatment regimens. For instance, patients with KRAS G12D mutations may benefit from enrollment in clinical trials investigating novel targeted agents or combination therapies.

Personalized therapy also involves considering co-occurring mutations and tumor heterogeneity, which can influence drug resistance and effectiveness. This holistic approach improves the likelihood of achieving durable responses.

Challenges and Future Perspectives

While the progress in KRAS G12D targeted therapy is encouraging, several challenges remain. Drug resistance mechanisms, such as secondary KRAS mutations or activation of alternative signaling pathways, can limit long-term treatment success.

Additionally, ensuring the safety and tolerability of new agents is critical, as off-target effects may impact normal cellular functions. Balancing efficacy with quality of life remains a priority for patients and providers.

Looking ahead, combination strategies that pair KRAS G12D inhibitors with other targeted drugs, immunotherapies, or chemotherapy hold great promise. Advancements in artificial intelligence and machine learning are also accelerating drug discovery and patient stratification.

Emerging Clinical Trials

Numerous clinical trials are underway to evaluate the safety and efficacy of KRAS G12D targeted therapies. These studies are crucial for translating laboratory findings into real-world treatments, offering hope to patients with limited options.

Participation in clinical trials also provides access to cutting-edge therapies and contributes to expanding the scientific understanding of KRAS-driven cancers.

Empowering Patients Through Knowledge

For patients diagnosed with cancers harboring KRAS G12D mutations, staying informed about emerging therapies and diagnostic tools is empowering. Engaging in discussions

with healthcare providers about genetic testing, clinical trial options, and personalized treatment plans can significantly impact outcomes.

Support networks and patient advocacy groups play an essential role in disseminating information and providing emotional support throughout the treatment journey.

Overall, the landscape of kras g12d targeted therapy is rapidly evolving, transforming what was once a bleak prognosis into a landscape of hope and possibility. As science continues to unravel the intricacies of KRAS biology, tailored treatments for KRAS G12D-driven cancers are becoming an attainable reality.

Frequently Asked Questions

What is KRAS G12D mutation?

KRAS G12D is a specific mutation in the KRAS gene where glycine (G) is replaced by aspartic acid (D) at codon 12. This mutation leads to continuous activation of the KRAS protein, promoting cancer cell growth.

Why is KRAS G12D targeted therapy important?

KRAS G12D targeted therapy is important because this mutation is common in several cancers, including pancreatic, colorectal, and lung cancers, and it has been historically difficult to target with drugs. Targeted therapy aims to inhibit the mutant protein and improve treatment outcomes.

Are there any FDA-approved drugs targeting KRAS G12D?

As of now, there are no FDA-approved drugs specifically targeting KRAS G12D, but several clinical trials are ongoing to develop inhibitors or therapies targeting this mutation.

How do KRAS G12D inhibitors work?

KRAS G12D inhibitors work by specifically binding to the mutant KRAS protein, preventing it from activating downstream signaling pathways that promote cancer cell proliferation and survival.

What types of cancers are most associated with KRAS G12D mutations?

KRAS G12D mutations are most commonly found in pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer.

What are the challenges in developing KRAS G12D targeted therapies?

Challenges include the high affinity of KRAS for GTP/GDP making it difficult to inhibit, the similarity of mutant and wild-type KRAS, and the complexity of downstream signaling pathways.

Are there any promising clinical trials for KRAS G12D targeted therapies?

Yes, several clinical trials are investigating new molecules such as KRAS G12D-specific inhibitors, siRNA therapies, and combination therapies to effectively target KRAS G12D mutations.

Can KRAS G12D targeted therapy be combined with other treatments?

Yes, combining KRAS G12D targeted therapies with chemotherapy, immunotherapy, or other targeted agents is being explored to improve efficacy and overcome resistance.

How is KRAS G12D mutation detected in patients?

KRAS G12D mutation is typically detected through genetic testing methods such as PCR, next-generation sequencing (NGS), or liquid biopsy using tumor tissue or blood samples.

What is the future outlook for KRAS G12D targeted therapy?

The future outlook is promising, with ongoing research and clinical trials aiming to develop effective and selective inhibitors, which could significantly improve treatment options and outcomes for patients with KRAS G12D-mutant cancers.

Additional Resources

Advancements and Challenges in KRAS G12D Targeted Therapy

kras g12d targeted therapy represents one of the most promising frontiers in precision oncology, particularly for cancers driven by mutations in the KRAS gene. KRAS mutations are among the most frequently occurring oncogenic alterations in human cancers, implicated in approximately 25-30% of all malignancies. The G12D variant, characterized by a glycine-to-aspartic acid substitution at codon 12, is notably prevalent in pancreatic, colorectal, and non-small cell lung cancers (NSCLC). Over the past decade, significant efforts have been dedicated to developing targeted therapies aimed specifically at KRAS G12D, striving to overcome the historic challenges posed by this oncogene’s “undruggable” reputation.

Understanding KRAS G12D Mutation and Its Clinical Significance

KRAS is a member of the RAS family of GTPases, acting as a molecular switch that controls cell proliferation, differentiation, and survival through downstream signaling pathways such as MAPK/ERK and PI3K/AKT. Mutations at codon 12, including G12D, lock KRAS in a constitutively active GTP-bound state, resulting in persistent oncogenic signaling. Among KRAS mutations, G12D is particularly aggressive and associated with poor prognosis. For instance, in pancreatic ductal adenocarcinoma (PDAC), KRAS G12D mutations are present in up to 45% of cases and correlate with therapy resistance and rapid disease progression.

Due to these factors, KRAS G12D targeted therapy is a high priority in oncological research, as effective inhibitors could dramatically improve outcomes for patients suffering from these difficult-to-treat cancers.

Historical Challenges in Targeting KRAS G12D

Targeting KRAS has long been considered a monumental challenge in drug development. The protein’s high affinity for GTP/GDP and lack of suitable binding pockets thwarted efforts to create small molecule inhibitors. Additionally, the similarity among RAS isoforms complicated the design of mutation-specific drugs that would spare wild-type KRAS to minimize toxicity.

Unlike the KRAS G12C mutation, for which covalent inhibitors like sotorasib and adagrasib have gained FDA approval, KRAS G12D lacks a reactive cysteine residue that allows for direct covalent binding. This distinction has delayed the development of effective KRAS G12D inhibitors, necessitating alternative approaches such as non-covalent small molecules, peptide-based therapies, and indirect targeting strategies.

Emerging Strategies in KRAS G12D Targeted Therapy

Direct Small Molecule Inhibitors

Recent advances in structural biology and medicinal chemistry have enabled the discovery of novel compounds capable of selectively binding to KRAS G12D. Non-covalent inhibitors, such as MRTX1133 developed by Mirati Therapeutics, have shown potent and selective inhibition of KRAS G12D in preclinical models. MRTX1133 binds to the inactive GDP-bound form of KRAS G12D, preventing its activation and subsequent downstream signaling.

Preclinical studies demonstrated tumor regression in mouse models of pancreatic cancer harboring the KRAS G12D mutation, sparking significant interest in clinical trials. Early-phase trials are currently underway to assess safety, pharmacokinetics, and efficacy in humans, with anticipation high for the clinical translation of these findings.

Indirect Targeting Approaches

Given the complexity of directly inhibiting KRAS G12D, alternative strategies focus on disrupting the downstream signaling pathways or synthetic lethal interactions:

- **MEK and ERK inhibitors:** These target effectors downstream of KRAS, aiming to block aberrant signaling. While promising, monotherapy with MEK inhibitors has shown limited success due to adaptive resistance mechanisms.
- **SHP2 inhibitors:** SHP2 acts as a facilitator of RAS activation. Inhibiting SHP2 may suppress KRAS-driven signaling indirectly and is being evaluated in combination with other agents.
- **Immune modulation:** KRAS mutations can alter the tumor microenvironment. Combining targeted therapies with immunotherapies, such as checkpoint inhibitors, holds potential for synergistic effects.

RNA-Based Therapeutics

Advances in RNA interference (RNAi) and antisense oligonucleotides (ASOs) have opened possibilities for silencing mutant KRAS transcripts. For KRAS G12D, siRNA molecules encapsulated in lipid nanoparticles are being designed to selectively degrade mutant mRNA, reducing protein expression. While still in early stages, this modality offers a novel avenue for targeting KRAS mutations that are elusive to small molecule inhibitors.

Comparative Landscape: KRAS G12D Versus G12C Targeted Therapies

The success of KRAS G12C inhibitors has reshaped the oncology landscape, providing a roadmap for G12D-targeted drug development. However, key differences remain:

- **Binding site accessibility:** G12C inhibitors capitalize on the unique cysteine residue for covalent binding, whereas G12D requires alternative binding mechanisms due to the absence of such residues.
- **Prevalence and cancer types:** G12D is more prevalent in pancreatic and colorectal

cancers, both of which exhibit complex tumor biology and dense stroma, complicating drug delivery.

- **Treatment response:** G12C-mutant NSCLC patients have experienced rapid clinical benefits, while G12D therapies are yet to demonstrate comparable efficacy in trials.

These distinctions underscore the necessity for tailored therapeutic designs and delivery systems to effectively target KRAS G12D.

Current Clinical Trials and Future Directions

Several clinical trials are underway to evaluate KRAS G12D targeted therapies, primarily focusing on agents like MRTX1133 and combination regimens involving SHP2 inhibitors or immune checkpoint blockade. Early-phase studies aim to establish safety profiles and optimal dosing, while exploratory endpoints include tumor response and biomarker validation.

Beyond small molecule inhibitors, innovative platforms such as adoptive T-cell therapies targeting KRAS G12D neoantigens are in development. These personalized immunotherapies harness the patient’s immune system to recognize and eradicate cancer cells harboring the mutation.

The future of KRAS G12D targeted therapy likely involves integrated strategies combining direct inhibitors, pathway modulators, and immunotherapies. Biomarker-driven patient selection and understanding resistance mechanisms will be critical to advancing these treatments.

Challenges and Considerations in Clinical Implementation

Despite promising advances, several challenges remain:

- **Drug resistance:** Tumor heterogeneity and adaptive signaling can lead to resistance, necessitating combination therapies.
- **Toxicity management:** Off-target effects on normal tissues with RAS signaling require careful monitoring.
- **Drug delivery:** Pancreatic and colorectal tumors present physical barriers that limit drug penetration.
- **Patient selection:** Accurate molecular diagnostics are essential to identify candidates for KRAS G12D targeted therapy.

Addressing these issues demands multidisciplinary collaboration and continued research investment.

As research progresses, the landscape of kras g12d targeted therapy continues to evolve, offering hope for patients with historically intractable cancers. With a combination of scientific innovation and clinical rigor, the goal of transforming KRAS G12D from an undruggable target to a manageable condition is becoming increasingly attainable.

Kras G12d Targeted Therapy

kras g12d targeted therapy: RAS Drug Discovery Adrian Gill, Kevan M. Shokat, 2024-10-08 KRAS Drug Discovery: Past, Present and Future is a comprehensive overview of the state-of-the-art medicinal chemistry approaches towards targeting the formerly undruggable oncogene, KRAS. It includes Seminal medicinal chemistry case histories of KRASG12C inhibitors such as Sotorosib, the first approved KRASG12C inhibitor for NSCLC, alongside the latest advances towards identification of in vivo tools and development candidates targeting KRAS G12D, KRAS G13C and other mutations. The book also provides the reader with a comprehensive overview of the in vitro assay systems, in vivo pharmacology xenograft models and chemical biology tools available to characterize small molecule inhibitors of KRAS. - Highlights key structure-based drug design (SBDD) innovations to generate potency and selectivity vs. KRAS - Analyzes medicinal chemistry case histories for seminal contributions to the KRAS field - Provides an overview of in vitro and in vivo methods for drugging KRAS

kras g12d targeted therapy: Emerging Talents in Pharmacology of Anti-Cancer Drugs 2022 Husain Yar Khan, Khuloud Bajbouj, Mai F. Tolba, 2023-05-16

kras g12d targeted therapy: Targeted cancer therapies, from small molecules to antibodies, volume II Zhe-Sheng Chen, Yunkai Zhang, Jian-ye Zhang, Yan-yan Yan, 2023-07-27

kras g12d targeted therapy: Combining chemo-radio therapy and immunotherapy for cancers—perfect mix of old and new Jian Zhang, Linlang Guo, Clare Y Slaney, Feng-Ming Kong, 2023-07-10

kras g12d targeted therapy: Understanding the Immuno-Oncological Mechanism of Cancer Using Systems Immunology Approaches Rifat Hamoudi, Daniel Olive, Lucia Conti, Alexander John MacRobert, 2024-01-02

kras g12d targeted therapy: *Animal Models for the Development of Cancer Immunotherapy* Seng-Lai Tan, 2022-08-23 Animal Models for the Development of Cancer Immunotherapy Provides readers with a clear understanding of the value and challenges of using common and emerging preclinical models in cancer immunotherapy research and development. Animal models are essential tools for studying a range of issues in preclinical and clinical research on therapies targeting cancerous tumors. As clinical trials of advances in cancer immunotherapy are predicted to outpace preclinical research in the near future, there remains an urgent need to develop better animal models for preclinical evaluation of novel modulators. Animal Models for the Development of Cancer Immunotherapy provides a detailed overview of different preclinical model systems for development of novel cancer immunotherapies while highlighting how key aspects of individual models translate into clinical findings. Covering the introduction, development, and therapeutic applications of animal models for cancer immunotherapy, this comprehensive volume helps pharmacologists identify suitable animal models, design pharmacological or translational studies, and advance their mechanistic understanding of therapeutic agents, and increase the possibility of success for novel immunotherapies in clinical settings. Chapters written by prominent leaders in the field address

specific models that evaluate immuno-oncology drugs are supported by in-depth case studies and extensive references throughout. Emphasizes the importance of modeling tumor metastasis in preclinical models for efficient translation of findings into the clinic Explores recently discovered mechanisms of resistance and their preclinical modeling Highlights the unique characteristics and features of autologous and allogeneic approaches for humanization of mouse models Reviews development of bone marrow-liver-thymus (BLT) immune humanized mice and emerging alternative models such as genetically engineered mouse models (GEMM) Discusses alternative animal models for cancer research such as severe combined immunodeficiency (SCID) pigs Animal Models for the Development of Cancer Immunotherapy is an essential resource for scientists and researchers in the pharmaceutical and biotechnology industries, medicinal chemists and biochemists, cell and molecular biologists, pharmacologists, immunologists, and clinicians.

kras g12d targeted therapy: Malignancies of the Upper Gastrointestinal Tract, An Issue of Hematology/Oncology Clinics of North America David H. Ilson, 2024-05-08 In this issue of Hematology/Oncology Clinics, guest editor David H. Ilson brings his considerable expertise to the topic of Malignancies of the Upper GI Tract. - Contains 12 relevant, practice-oriented topics including Advances in the Imaging of Esophageal and Gastroesophageal Junction Malignancies; Advances in Immunotherapy in Esophagogastric Cancer; Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer; Advances in the Surgical Management of Esophageal Cancer; and more. - Provides in-depth clinical reviews on malignancies of the upper GI tract, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

kras g12d targeted therapy: Targeted Therapies for Lung Cancer Ravi Salgia, 2019-06-26 This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.

kras g12d targeted therapy: A Beginner's Guide to Targeted Cancer Treatments and Cancer Immunotherapy Elaine Vickers, 2025-03-10 Demystifying the science behind new cancer treatments A clear and accessible guide written in everyday language for nurses and other healthcare professionals A Beginner’s Guide to Targeted Cancer Treatments and Cancer Immunotherapy helps readers understand the science behind many of the newer drug treatments for cancer. Assuming only a basic familiarity with cell biology, this easy-to-digest guide describes how our increased understanding of cancer has been translated into the creation of new cancer treatments with a wide range of targets. Gifted communicator and educator Dr. Elaine Vickers helps you understand the mechanisms of a wide range of individual targeted therapies and immunotherapies — enabling you to communicate effectively with your colleagues and patients. Concise chapters explain how new cancer drugs and immunotherapies work, discuss their benefits, identify their limitations, and more. Now in its second edition, this popular handbook is fully revised to reflect the latest developments in targeted drug therapies and immunotherapies. Entirely new chapters on advancements in various immunotherapies are accompanied by more than 100 new and updated color illustrations. Provides an up-to-date overview of relevant treatment targets for all major cancer types, including hematological cancers Describes cancer biology and the relationship

between cancer and the immune system Offers valuable insights into cell communication pathways as a common target Covers small molecule drugs, antibody-based treatments, and cellular therapies, including novel immunotherapies A Beginner's Guide to Targeted Cancer Treatments and Cancer Immunotherapy is a must-have resource for trainees, practicing nurses, and other healthcare professionals involved in the care of cancer patients, as well as non-specialists who encounter cancer data or cancer terminology in their field.

kras g12d targeted therapy: *DeVita, Hellman, and Rosenberg's Cancer* Vincent T DeVita Jr, Steven A Rosenberg, Theodore S Lawrence, 2022-09-21 The standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and presentation. Drs. Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg oversee an outstanding team of expert contributing authors who keep you up to date and fully informed in this fast-changing field. This award-winning reference is also continually updated on Health Library and VitalSource platforms for the life of the edition.

kras g12d targeted therapy: Pancreatic Cancer Shubham Pant, 2023-11-07 Pancreatic cancer is a challenging and complex disease characterized by a dense fibrotic stroma and an immunosuppressive tumor microenvironment. Until recently, there were no predictive biomarkers to personalize selection of targeted or biologic therapies as a part of standard of care treatment. Moreover, the regulatory immune population of cells creates a "cold", non-immunogenic tumor that is resistant to immunotherapies including checkpoint inhibitors. However, in the last few years, there has been substantial progress in our understanding of the role mutations in the pathogenesis of disease leading to increased adoption of germline and next generation sequencing to identify mutations and fusions to optimize selection of therapies and select patients for clinical trials of targeted agents. This book provides a comprehensive, global overview on therapy for pancreatic cancer, exploring approved therapies and focusing on the "Next" in drug development including molecularly targeted therapy and efforts at "Drugging the Undruggable": the KRAS mutation. It also addresses efforts at targeting the inhospitable stroma to improve drug delivery to the tumor cells, incorporating ct DNA (liquid biopsies) in the care of patients and recent advances in immunotherapy. Pancreatic Cancer: Current Therapeutics and Future Directions will illuminate these challenges, review existing therapeutics, and highlight current and future efforts to improve outcomes in this devastating disease. Useful to physicians, fellows, medical students, residents, physician assistants, nurse practitioners, pharmaceutical companies and researchers interested in pancreatic cancer, it will first explain management of localized disease including resectability and adjuvant and neoadjuvant therapies. Targeted therapies including molecular, immunotherapy, stroma and role of ctDNA or "liquid biopsies" will be addressed. Finally, the book will explore the important role of pain management, diet and exercise in improving outcomes in pancreatic cancer.

kras g12d targeted therapy: *Advances in the surgical management of gastric and colorectal cancers* Kristoffer Andresen, Bo Zhang, Paola Parente, Ye Zhou, 2023-11-17

kras g12d targeted therapy: Biomarkers, Functional Mechanisms, and Therapeutic Potentials in Gastrointestinal Cancers Zequn Li, Kui Zhang, Qun Zhang, Huashan Shi, Dongshi Chen, 2023-11-17 Significant changes in diet, environment, and population increase gastrointestinal cancer morbidity. A growing number of novel biomarkers and underlying mechanisms are being elucidated, some of which may even conflict with assumptions of past decades. Therefore, collecting recent findings on novel diagnostic/prognostic factors, biomarkers, and/or risk factors in gastrointestinal cancers is a prerequisite for a better understanding of the disease. Despite remarkable progressions in surgical treatments and chemotherapies, the prognosis of gastrointestinal cancer is far from satisfactory due to the high occurrence of drug resistance. Based on the identification of novel biomarkers as well as their underlying mechanisms, targeted drug development will provide significant complementary therapeutic effects to conventional chemoradiotherapies. High-throughput methods such as next-generation sequencing on RNA level and mass spectrometry on protein/lipid/metabolite level serve as efficient strategies for biomarker

identification and drug development. This Research Topic aims at presenting recent advances on gastrointestinal cancer biomarkers and their underlying functional mechanisms, providing a better understanding of carcinogenesis, tumor progression, tumor relapse, as well as drug resistance. This will subsequently contribute to the development of novel therapeutic interventions targeting gastrointestinal cancers, thus improving patients' outcomes.

kras g12d targeted therapy: Advancing Cancer Therapy: Innovative Strategies Targeting Immune Evasion and Metabolic Modulation Ana Luísa De Sousa-Coelho, Andrés Méndez Lucas, Nuno Miguel Nunes, Francesca Rapino, Mónica Teotónio Fernandes, 2025-10-01 Cancer is one of the leading causes of death globally, and although there is accumulating knowledge about the mechanisms of cancer development and progression, the cancer burden continues to escalate. This greatly impacts the patients, their families, communities, and health systems. In some instances, cancer can be prevented. If identified early, it is more likely to respond to first-line treatments like surgery, radiotherapy, hormonal treatments, and more recent targeted biological therapies and immunotherapies. However, some cancers may develop resistance to therapies and, when diagnosed in advanced stages or at relapse, current therapies may be largely ineffective. Therefore, there is a need to better understand cancer and unveil new targets and approaches for treating it more effectively. In this context, immune evasion and altered cellular metabolism have emerged as hallmarks of cancer and hot topics in cancer research. Unlike conventional cancer therapies, novel approaches that promise to alleviate the current cancer burden are emerging. New discoveries unveiled important targets for therapy translating to clinical practice namely immunotherapies, which unfortunately are ineffective in several types of cancer and patients. Recently, metabolism shifts have been increasingly recognized as a target to improve cancer responses to chemotherapy and immunotherapy. This Research Topic aims to highlight the most recent advances in the field of cancer therapy, focusing on new approaches that go beyond traditional ones in the treatment of any type of cancer. Main themes include, but are not limited to: • Tumor microenvironment and metabolic modulation • Novel targets for immunotherapy These approaches may include drug repurposing and advanced delivery strategies, among others, that will allow to advance precision medicine. In this Research Topic we welcome submissions such as Brief Research Report, Case Report, Clinical Trial, Mini Review, Review, Original Research, and Systematic Review. Our objective is to produce a high-quality article collection covering new promising discoveries and innovative approaches, either at the pre-clinical or clinical levels.

kras g12d targeted therapy: Genetic and proteomic biomarkers in solid tumor detection and treatment Jitian Li, Apeng Chen, Ruowen Zhang, Changwei Li, Jian-Guo Zhou, 2023-06-07

kras g12d targeted therapy: Oncogenic RAS-dependent Reprogramming of Cellular Plasticity Alessandro Rimessi, Georgia Konstantinidou, 2020-06-15

kras g12d targeted therapy: Lung Cancer, An Issue of Hematology/Oncology Clinics of North America, E-Book Sarah B. Goldberg, Roy S. Herbst, 2023-05-11 In this issue of Hematology/Oncology Clinics, guest editors Drs. Sarah B. Goldberg and Roy S. Herbst bring their considerable expertise to the topic of Lung Cancer. Top experts in the field cover key topics such as state-of-the-art pathologic and molecular testing; neoadjuvant vs. adjuvant therapy for early-stage NSCLC; new therapies on the horizon (immunotherapy, ADCs, etc.); supportive care and symptom management; smoking cessation; and more. - Contains 15 relevant, practice-oriented topics including lung cancer screening; advances in surgical techniques for lung cancer; non-surgical therapy for early-stage lung cancer; locally advanced lung cancer; what's new in small cell lung cancer; and more. - Provides in-depth clinical reviews on lung cancer, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

kras g12d targeted therapy: How to Select Patients With Thoracic Cancers for Immunotherapy-Chemotherapy or Immunotherapy-Angiogenesis Inhibitor Combinations? Weimin Mao, Herbert Yu, Qibin Song, Kai Wang, 2022-11-28

kras g12d targeted therapy: Genetic Variants as Targets for Immunotherapy of Hematological Tumors Marieke Griffioen, Claude Perreault, Robbert Spaapen, 2020-12-15 This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.

kras g12d targeted therapy: New Progress in Cancer Biomarkers and Therapy Guohui Sun, Wei Zhang, Jianhua Wa, Chengwei He, 2024-03-18 As we know, cancer is an important disease threatening human health. According to the latest statistics in “Global Cancer Statistics 2020”, cancer is expected to overtake cardiovascular disease as the leading cause of premature death in most countries this century. That sounds pretty terrible, but it is believed that this situation should be better along with the advances in tumor biology. There is no doubt that biomarkers have very significant clinical implications, which can be used for early diagnosis, monitoring progress, and predicting the prognosis of cancer.

Related to kras g12d targeted therapy

KRAS - Wikipedia KRAS acts as a molecular on/off switch, using protein dynamics. Once it is allosterically activated, it recruits and activates proteins necessary for the propagation of growth factors, as well as

What’s new in KRAS mutation research? - MD Anderson Cancer The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers

KRAS gene: MedlinePlus Genetics The KRAS gene provides instructions for making a protein called K-Ras that is part of a signaling pathway known as the RAS/MAPK pathway. Learn about this gene and related health conditions

Cracking KRAS | Amgen KRAS mutations are among the most common drivers of cancer. This mutation plays a major role in helping tumors grow and survive, especially in lung, colon and pancreatic

Vaccine Targeting KRAS in Pancreatic and Colorectal Cancer The new vaccine is able to activate immune cells that target different KRAS mutations called KRAS -G12D and KRAS -G12R, which drive about 90% of pancreatic cancers

KRAS and Lung Cancer - American Lung Association The KRAS gene normally serves as an information hub for signals that lead to cell growth. When there is a mutation in KRAS, it signals too much and cells grow, which causes

What is KRAS Cancer KRAS is the most common biomarker associated with lung, colorectal, pancreatic plus other cancers. Identified 50 years ago, researchers have learned that different sub-types of KRAS

Definition of KRAS gene - NCI Dictionary of Cancer Terms A gene that makes a protein that is involved in cell signaling pathways that control cell growth, cell maturation, and cell death. The natural, unchanged form of the gene is called wild-type KRAS

KRAS Mutation Status and Outcomes in Metastatic Pancreatic There is a lack of high-volume data exploring the outcomes of patients with metastatic PDAC treated with cytotoxic regimens based on the tumor-specific KRAS

Exploring KRAS: A precision approach in oncology - Merck KRAS is one of the most frequently mutated oncogenes found in cancer. In healthy cells, KRAS serves as an on-off switch that regulates cell growth. However, when the gene is

KRAS - Wikipedia KRAS acts as a molecular on/off switch, using protein dynamics. Once it is allosterically activated, it recruits and activates proteins necessary for the propagation of growth

factors, as well as

What’s new in KRAS mutation research? - MD Anderson Cancer The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers

KRAS gene: MedlinePlus Genetics The KRAS gene provides instructions for making a protein called K-Ras that is part of a signaling pathway known as the RAS/MAPK pathway. Learn about this gene and related health conditions

Cracking KRAS | Amgen KRAS mutations are among the most common drivers of cancer. This mutation plays a major role in helping tumors grow and survive, especially in lung, colon and pancreatic

Vaccine Targeting KRAS in Pancreatic and Colorectal Cancer The new vaccine is able to activate immune cells that target different KRAS mutations called KRAS -G12D and KRAS -G12R, which drive about 90% of pancreatic cancers

KRAS and Lung Cancer - American Lung Association The KRAS gene normally serves as an information hub for signals that lead to cell growth. When there is a mutation in KRAS, it signals too much and cells grow, which causes

What is KRAS Cancer KRAS is the most common biomarker associated with lung, colorectal, pancreatic plus other cancers. Identified 50 years ago, researchers have learned that different sub-types of KRAS

Definition of KRAS gene - NCI Dictionary of Cancer Terms A gene that makes a protein that is involved in cell signaling pathways that control cell growth, cell maturation, and cell death. The natural, unchanged form of the gene is called wild-type KRAS

KRAS Mutation Status and Outcomes in Metastatic Pancreatic There is a lack of high-volume data exploring the outcomes of patients with metastatic PDAC treated with cytotoxic regimens based on the tumor-specific KRAS

Exploring KRAS: A precision approach in oncology - Merck KRAS is one of the most frequently mutated oncogenes found in cancer. In healthy cells, KRAS serves as an on-off switch that regulates cell growth. However, when the gene is

KRAS - Wikipedia KRAS acts as a molecular on/off switch, using protein dynamics. Once it is allosterically activated, it recruits and activates proteins necessary for the propagation of growth factors, as well as

What’s new in KRAS mutation research? - MD Anderson Cancer The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers

KRAS gene: MedlinePlus Genetics The KRAS gene provides instructions for making a protein called K-Ras that is part of a signaling pathway known as the RAS/MAPK pathway. Learn about this gene and related health conditions

Cracking KRAS | Amgen KRAS mutations are among the most common drivers of cancer. This mutation plays a major role in helping tumors grow and survive, especially in lung, colon and pancreatic

Vaccine Targeting KRAS in Pancreatic and Colorectal Cancer The new vaccine is able to activate immune cells that target different KRAS mutations called KRAS -G12D and KRAS -G12R, which drive about 90% of pancreatic cancers

KRAS and Lung Cancer - American Lung Association The KRAS gene normally serves as an information hub for signals that lead to cell growth. When there is a mutation in KRAS, it signals too much and cells grow, which causes

What is KRAS Cancer KRAS is the most common biomarker associated with lung, colorectal, pancreatic plus other cancers. Identified 50 years ago, researchers have learned that different sub-types of KRAS

Definition of KRAS gene - NCI Dictionary of Cancer Terms A gene that makes a protein that is involved in cell signaling pathways that control cell growth, cell maturation, and cell death. The

natural, unchanged form of the gene is called wild-type KRAS

KRAS Mutation Status and Outcomes in Metastatic Pancreatic There is a lack of high-volume data exploring the outcomes of patients with metastatic PDAC treated with cytotoxic regimens based on the tumor-specific KRAS

Exploring KRAS: A precision approach in oncology - Merck KRAS is one of the most frequently mutated oncogenes found in cancer. In healthy cells, KRAS serves as an on-off switch that regulates cell growth. However, when the gene is

KRAS - Wikipedia KRAS acts as a molecular on/off switch, using protein dynamics. Once it is allosterically activated, it recruits and activates proteins necessary for the propagation of growth factors, as well as

What's new in KRAS mutation research? - MD Anderson Cancer The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers

KRAS gene: MedlinePlus Genetics The KRAS gene provides instructions for making a protein called K-Ras that is part of a signaling pathway known as the RAS/MAPK pathway. Learn about this gene and related health conditions

Cracking KRAS | Amgen KRAS mutations are among the most common drivers of cancer. This mutation plays a major role in helping tumors grow and survive, especially in lung, colon and pancreatic

Vaccine Targeting KRAS in Pancreatic and Colorectal Cancer The new vaccine is able to activate immune cells that target different KRAS mutations called KRAS -G12D and KRAS -G12R, which drive about 90% of pancreatic cancers

KRAS and Lung Cancer - American Lung Association The KRAS gene normally serves as an information hub for signals that lead to cell growth. When there is a mutation in KRAS, it signals too much and cells grow, which causes

What is KRAS Cancer KRAS is the most common biomarker associated with lung, colorectal, pancreatic plus other cancers. Identified 50 years ago, researchers have learned that different sub-types of KRAS

Definition of KRAS gene - NCI Dictionary of Cancer Terms A gene that makes a protein that is involved in cell signaling pathways that control cell growth, cell maturation, and cell death. The natural, unchanged form of the gene is called wild-type KRAS

KRAS Mutation Status and Outcomes in Metastatic Pancreatic There is a lack of high-volume data exploring the outcomes of patients with metastatic PDAC treated with cytotoxic regimens based on the tumor-specific KRAS

Exploring KRAS: A precision approach in oncology - Merck KRAS is one of the most frequently mutated oncogenes found in cancer. In healthy cells, KRAS serves as an on-off switch that regulates cell growth. However, when the gene is

KRAS - Wikipedia KRAS acts as a molecular on/off switch, using protein dynamics. Once it is allosterically activated, it recruits and activates proteins necessary for the propagation of growth factors, as well as

What's new in KRAS mutation research? - MD Anderson Cancer The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers

KRAS gene: MedlinePlus Genetics The KRAS gene provides instructions for making a protein called K-Ras that is part of a signaling pathway known as the RAS/MAPK pathway. Learn about this gene and related health conditions

Cracking KRAS | Amgen KRAS mutations are among the most common drivers of cancer. This mutation plays a major role in helping tumors grow and survive, especially in lung, colon and pancreatic

Vaccine Targeting KRAS in Pancreatic and Colorectal Cancer The new vaccine is able to activate immune cells that target different KRAS mutations called KRAS -G12D and KRAS -G12R,

which drive about 90% of pancreatic cancers

KRAS and Lung Cancer - American Lung Association The KRAS gene normally serves as an information hub for signals that lead to cell growth. When there is a mutation in KRAS, it signals too much and cells grow, which causes

What is KRAS Cancer KRAS is the most common biomarker associated with lung, colorectal, pancreatic plus other cancers. Identified 50 years ago, researchers have learned that different sub-types of KRAS

Definition of KRAS gene - NCI Dictionary of Cancer Terms A gene that makes a protein that is involved in cell signaling pathways that control cell growth, cell maturation, and cell death. The natural, unchanged form of the gene is called wild-type KRAS

KRAS Mutation Status and Outcomes in Metastatic Pancreatic There is a lack of high-volume data exploring the outcomes of patients with metastatic PDAC treated with cytotoxic regimens based on the tumor-specific KRAS

Exploring KRAS: A precision approach in oncology - Merck KRAS is one of the most frequently mutated oncogenes found in cancer. In healthy cells, KRAS serves as an on-off switch that regulates cell growth. However, when the gene is

Related to kras g12d targeted therapy

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer (Seeking Alpha2mon) Enrollment is ongoing in U.S. Phase 1/2a trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D advanced solid tumors KRAS G12D mutation is the most prevalent KRAS mutation in human

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer (Seeking Alpha2mon) Enrollment is ongoing in U.S. Phase 1/2a trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D advanced solid tumors KRAS G12D mutation is the most prevalent KRAS mutation in human

Future Directions and Conclusion (Targeted Oncology23d) A panelist discusses how this is an exciting time for pancreatic cancer treatment with the development of RAS inhibitors

Future Directions and Conclusion (Targeted Oncology23d) A panelist discusses how this is an exciting time for pancreatic cancer treatment with the development of RAS inhibitors

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer (Business Wire4mon) BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer (Business Wire4mon) BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 202 (Business Wire1mon) BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive,

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 202 (Business Wire1mon) BOSTON--(BUSINESS WIRE)--Verastem Oncology

(Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive,

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer (2d) New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A,

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer (2d) New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A,

1SLXN : Why Is Silexion Therapeutics Stock Trading Higher On Thursday? (Benzinga.com2mon) SIL204 inhibited up to 97% of pancreatic cancer cells with KRAS mutations in preclinical studies. Nearly 90% inhibition seen in colorectal cancer cells; Phase 2/3 trial expected in Q2 2026. Get

1SLXN : Why Is Silexion Therapeutics Stock Trading Higher On Thursday? (Benzinga.com2mon) SIL204 inhibited up to 97% of pancreatic cancer cells with KRAS mutations in preclinical studies. Nearly 90% inhibition seen in colorectal cancer cells; Phase 2/3 trial expected in Q2 2026. Get

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib (Nasdaq2mon) Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib (Nasdaq2mon) Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer (The Bakersfield Californian2mon) Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer (The Bakersfield Californian2mon) Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug

Related Articles

- temtem leveling guide 2022
- music language and the brain
- bamboo therapy dallas texas

Back to Home